Bepranemab
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody. Bepranemab targets the central portion of tau, specifically amino acids 235 to 246. Bepranemab can be used for Alzheimer’s disease (AD) research[1][2].
Product Specifications
CAS Number
2244960-75-4
Product Name Alternative
UCB 0107
UNSPSC
12352203
Target
Tau Protein
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/bepranemab.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
[Bepranemab]
Molecular Weight
(145.52 kDa)
References & Citations
[1]Matthew E Barton, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003. Alzheimer's & Dementia. 31 December 2021.|[2]Neațu M, et al. Monoclonal Antibody Therapy in Alzheimer's Disease. Pharmaceutics. 2023 Dec 29;16 (1) :60.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
A03237-2-carrier-free 100 µg/Vial
Anti-MCP2/CCL8 Antibody Picoband®, Carrier-free
Sign In for Pricing
View Details 
MBS1016647-01 0.02 mg (E-Coli)
Recombinant Bacillus subtilis Phosphatidylserine decarboxylase proenzyme (psd)
Sign In for Pricing
View Details